NeuroMab™ Anti-EGFR Antibody(NRP-0422-P1174)

Figure 1 shows the results of an assay measuring the ability of antibodies 2F8 and A12 to block the binding of IGF-I to immobilized soluble IGF-IR. A12 antibodies with kappa or lambda light chain constant regions were tested.

Figure 2 shows IGF-I-mediated inhibition of receptor phosphorylation.

Inhibitory effect of antibodies A12 and 2F8 on MCF7 breast cancer cells.

Figure 3 shows the inhibition of IGF-I mediated phosphorylation of downstream effector molecules by antibodies A12 and 2F8.

Figure 4 shows receptor internalization.

The figure shows the degradation of total cellular IGF-IR after chronic treatment with Al2.

Figure 5 shows receptor internalization.

Figure 6 shows the effect of antibody A12 on 3H-thymidine incorporation in a mitotic assay.

Figure 7 shows the results of an assay measuring the ability of antibodies 2F8 and A12 (λ light chain) to block IGF-I binding to MCF7 cells.

Figure 8 shows the results of an assay measuring the ability of antibodies 2F8 and A12 to block insulin binding to ZR75-I cells.